These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10233785)

  • 41. [Is heart rate reduction beneficial to patients with heart insufficiency? Focus on beta-blockade].
    Henriksen OM; Gadsbøll N
    Ugeskr Laeger; 2002 Jan; 164(5):615-9. PubMed ID: 11871210
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hypertension and heart failure. Are there approaches for differential therapy?].
    Böhm M
    MMW Fortschr Med; 2000 Feb; 142(7):31-3. PubMed ID: 10832331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
    Saltzberg MT
    Rev Cardiovasc Med; 2004; 5 Suppl 4():S17-27. PubMed ID: 15627915
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
    Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
    Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts.
    Zausig YA; Stowe DF; Zink W; Grube C; Martin E; Graf BM
    Anesth Analg; 2006 Jun; 102(6):1646-52. PubMed ID: 16717301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A new drug against heart failure was retracted after an alarm about increased mortality].
    Lennholm B
    Lakartidningen; 1993 Aug; 90(32-33):2682-3. PubMed ID: 8361279
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effective milrinone therapy to a Duchenne muscular dystrophy patient with advanced congestive heart failure].
    Matsumura T; Saito T; Miyai I; Nozaki S; Kang J
    Rinsho Shinkeigaku; 1999 Jun; 39(6):643-8. PubMed ID: 10502990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Risk factors for dying among ibopamine users].
    de Graeff PA; Elferink AJ; Lekkerkerker JF
    Ned Tijdschr Geneeskd; 1999 May; 143(21):1114-5. PubMed ID: 10368748
    [No Abstract]   [Full Text] [Related]  

  • 50. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
    Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
    Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The flosequinan experience and its implications.
    Fath-Ordoubadi F
    Br J Hosp Med; 1993 Dec 15-1994 Jan 18; 50(11):683; author reply 683-4. PubMed ID: 8124555
    [No Abstract]   [Full Text] [Related]  

  • 52. Guidelines abstracted from consensus recommendations for the management of chronic heart failure.
    J Am Geriatr Soc; 2000 Nov; 48(11):1521-4. PubMed ID: 11083336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proper use of phosphodiesterase inhibitors according to the situations.
    Tanwiphongtrakun T; Inoue S; Furuya H
    Acta Anaesthesiol Taiwan; 2006 Sep; 44(3):183-5. PubMed ID: 17037008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Through the looking glass: a positive inotropic drug and ischemic preconditioning.
    Vander Heide RS; Marsh JD
    Circulation; 1997 Apr; 95(8):1989-91. PubMed ID: 9133503
    [No Abstract]   [Full Text] [Related]  

  • 55. Oral heart failure medications: an update for home health clinicians.
    Cheek DJ; Sherrod MM; Graulty R; Hawkins J
    Home Healthc Nurse; 2008; 26(10):600-11; quiz 612-3. PubMed ID: 19001915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy.
    Stevenson LW
    Circulation; 2003 Jul; 108(4):492-7. PubMed ID: 12885733
    [No Abstract]   [Full Text] [Related]  

  • 57. Inotropic therapy for heart failure: an evidence-based approach.
    Felker GM; O'Connor CM
    Am Heart J; 2001 Sep; 142(3):393-401. PubMed ID: 11526351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Home Inotropes and Other Palliative Care.
    Ginwalla M
    Heart Fail Clin; 2016 Jul; 12(3):437-48. PubMed ID: 27371519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extended release oral milrinone as an adjunct to heart failure therapy.
    Nanayakkara S; Bergin P; Mak V; Crannitch K; Kaye DM
    Intern Med J; 2017 Aug; 47(8):973-974. PubMed ID: 28782207
    [No Abstract]   [Full Text] [Related]  

  • 60. Role of cytokines in the syndrome of heart failure.
    Sasayama S; Matsumori A
    Intern Med; 1996 Jan; 35(1):60-3. PubMed ID: 8652941
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.